Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines

Antiviral Research

Volumn 88, Issue SUPPL., 2010, Pages

  Whaley, Kevin J ^a   Hanes, Justin ^b   Shattock, Robin ^c   Cone, Richard A ^d   Friend, David R ^e  

^a Mapp Biopharmaceutical Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Biopharmaceuticals; Microbicides; Nanoparticles; Safety; Vaccine; Vaginal immunity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYANOVIRIN N; DAPIVIRINE; DEFENSIN; DNA; ETHINYLESTRADIOL PLUS ETONOGESTREL; LECTIN; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; MONOCLONAL ANTIBODY; NANOPARTICLE; PROGESTERONE; RANTES; RECOMBINANT ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VACCINE;

BIOENGINEERING; COST; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; GEL; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRESERVATION; PRIORITY JOURNAL; RECTUM MUCOSA; REVIEW; SEXUALLY TRANSMITTED DISEASE; UNSAFE SEX; VACCINATION; VAGINA MUCOSA; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; DISEASE MODELS, ANIMAL; DOSAGE FORMS; DRUG AND NARCOTIC CONTROL; EXCIPIENTS; FEMALE; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MICE; NANOPARTICLES; REVERSE TRANSCRIPTASE INHIBITORS; VAGINA; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649419410     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.006     Document Type: Review

References (60)

1. Achilles S.L., Shete P.B., Whaley K.J., Moench T.R., Cone R.A. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex. Transm. Dis. 2002, 29:655-664.
2. Adriaens E., Remon J.P. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex. Transm. Dis. 2008, 35:512-516.
3. Anderson D.J. Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J. Infect. Dis. 2010, 202:333-336.
4. Anderson D.J., Politch J.A., Nadolski A.M., Blaskewicz C.D., Pudney J., Mayer K.H. Trojan horse leukocytes for HIV prevention. AIDS 2010, 24:163-187.
5. Bourne N., Zaneveld L.J., Ward J.A., Ireland J.P., Stanberry L.R. Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin. Microbiol. Infect. 2003, 9:816-822.
6. Bernstein D.I., Stanberry L.R., Sacks S., Ayisi N.K., Gong Y.H., Ireland J., Mumper R.J., Holan G., Matthews B., McCarthy T., Bourne N. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 2003, 47:3784-3788.
7. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 2005, 42:14943-14948.
8. Cates W. Family planning: the essential link to achieving all eight Millennium Development Goals. Contraception 2010, 81:460-461.
9. Cerini F., Landay A., Gichinga C., Lederman M.M., Flyckt R., Starks D., Offord R.E., Le Gal F., Hartley O. Chemokine analogues show suitable stability for development as microbicides. J. Acquir. Immune Defic. Syndr. 2008, 49:472-476.
10. + T-cell-depleted rhesus macaques. J. Virol. 2001, 75:1547-1550.
11. Cone R.A., Hoen T., Wong X., Abusuwwa R., Anderson D.J., Moench T.R. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect. Dis. 2006, 6:90.
12. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
13. Cranage M., Sharpe S., Herrera C., Cope A., Dennis M., Berry N., Ham C., Heeney J., Rezk N., Kashuba A., Anton P., McGowan I., Shattock R. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008, 5:e157.
14. Doncel G.F., Clark M. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res. 2010, 88:S10-S18.
15. Feldblum P.J., Adeiga A., Bakare R., Wevill S., Lendvay A., Obadaki F., Olayemi M.O., Wang L., Nanda K., Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008, 3:e1474.
16. FDA, 2004. Challenge and Opportunity on the Critical Path to New Medical Products, Food and Drug Administration.
17. Friend D.R., Doncel G.F. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies. Antiviral Res. 2010, 88:S47-S54.
18. Fuchs E.J., Lee L.A., Torbenson M.S., Parsons T.L., Bakshi R.P., Guidos A.M., Wahl R.L., Hendrix C.W. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J. Infect. Dis. 2007, 195:703-710.
19. Gaertner H., Cerini F., Escola J.-M., Kuenzi G., Melott I.A., Offord R., Rossitto-Borlat I., Nedellec R., Salkowitc J., Gorochov G., Mosier D., Hartley O. Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA 2008, 205:17706-17711.
20. Galen B.T., Martin A.P., Hazrati E., Garin A., Guzman E., Wilson S.S., Porter D.D., Lira S.A., Keller M.J., Herold B.C. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J. Infect. Dis. 2007, 195:1332-1339.
21. Garg S., Goldman D., Krumme M., Rohan L., Smoot S., Friend D.R. Advances in development, scale up and manufacturing of microbicide gels, films, and tablets. Antivir. Res. 2010, 88:S19-S28.
22. Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V., Gleba Y. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. USA 2006, 103:14701-14706.
23. Hladik F., Doncel G.F. Preventing mucosal HIV transmission with topical microbicides - challenges and opportunities. Antivir. Res. 2010, 88:S3-S9.
24. Hiatt A., Pauly M. Monoclonal antibodies from plants: A new speed record. Proc. Natl. Acad. Sci. USA 2006, 103:14645-14646.
25. Holt B.Y., Morowitz V.G., Ngo L., Harrison P.F., Whaley K.J., Pettifor A., Nguyen A.H. Microbicide preference among young women in California. J. Women's Health 2006, 15:281-294.
26. Huang C.C., Tang M., Zhang M.-Y., Majeed S., Montabara E., Stanfield R.L., Dimitrov D.S., Karber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-Containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
27. Huang Z., Phoolcharoen W., Lai H., Piensook K., Cardineau G., Zeitlin L., Whaley K.J., Arntzen C.J., Mason H.S., Chen Q. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol. Bioeng. 2010, 106:9-17.
28. Keele B.F., Giorgi E.E., Salazar-Gonzales J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kircherr J.J., Gao F., Anderson J.A., Ping L.-H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.A., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelops in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105:7552-7557.
29. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 2007, 104:1482-1487.
30. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and genedelivery to mucosal tissues. Adv. Drug Del. Rev. 2009, 61:158-171.
31. Lai S.K., Hida K., Shukair S., Wang Y.Y., Figueiredo A., Cone R., Hope T.J., Hanes J. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralizedhuman cervicovaginal mucus. J. Virol. 2009, 83:11196-11200.
32. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that humancervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. USA 2010, 107:598-603.
33. Li Q., Estes J.D., Schlievert P.M., Duan L., Brosnahan A.J., Southern P.J., Reilly C.S., Peterson M.L., Schultz-Darken N., Brunner K.G., Nephew K.R., Pambuccian S., Lifson J.D., Carlis J.V., Haase A.T. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038.
34. Lian Y., Srivastava I., Gómez-Román V.R., Megede J.Z., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P.A., Otten G., Ulmer J.B., Donnelly J.J., Rabussay D., Montefiori D., van Rensburg E.J., Barnett S.W. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 2005, 79:13338-13349.
35. Liu Y., Yu R., Xia Q., Jia L., Liu X., Lee P.P., Xu Q. Formulation development for preservation of lactobacillus as a live microbicide. Trends in Microbicide Formulations Workshop. CONRAD January 2010, 25:2010.
36. Maguire R.A., Bergman N., Phillips D.M. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex. Transm. Dis. 2001, 28:259-265.
37. Malcolm R.K., Edwards K.-L., Kiser P., Romano J., Smith T. Advances in microbicide vaginal rings. Antivir. Res. 2010, 88:S30-S39.
38. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 2006, 34:241-255.
39. Morris, G., Chindrove, S., Woodhall, S., Wiggins, R., Vcelar, B., Lacey, C. 2010. A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing antibodies (2FS, 2G12, 4E10) (MabGel). Microbicides 2010 (Pittsburgh, PA), LB1, p. 229.
40. Morrow K., Hendrix C. Clinical evaluation of microbicide formulations. Antivir. Res. 2010, 88:S40-S46.
41. Palliser D., Chowdhury D., Wang Q.Y., Lee S.J., Bronson R.T., Knipe D.M., Lieberman J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006, 439:89-94.
42. PATH and the Coalition Advancing Multipurpose Innovations (CAMI). 2010. Saving lives with multipurpose technology: Turning ideas into solutions for sexual and reproductive health. Seattle: PATH.
43. Phillips D.M., Zacharopoulos V.R. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 1998, 57:341-348.
44. Radomsky M.L., Whaley K.J., Cone R.A., Saltzman W.M. Controlled vaginal delivery of antibodies in the mouse. Biol. Reprod. 1992, 47:133-140.
45. Saltzman W.M., Radomsky M.L., Whaley K.J., Cone R.A. Antibody diffusion in human cervical mucus. Biophys. J. 1995, 55:508-515.
46. Schlievert P.M., Strandberg K.L., Brosnahan A.J., Peterson M.L., Pambuccian S.E., Nephew K.R., Brunner K.G., Schultz-Darken N.J., Haase A.T. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use.Antimicrob. Agents Chemother. 2008, 52:4448-4454.
47. Secchi M., Xu Q., Lusso P., Vangelista L. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Prot. Exp. Purif. 2009, 68:34-41.
48. Sherwood J., Zeitlin L., Whaley K., Cone R., Saltzman W. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat. Biotech. 1996, 14:468-471.
49. Simons-Rudolph A.P., Woodsong C., Koo H.P. Modeling the social context of microbicide use. Microbicide Quarterly 2008, 6:1-11.
50. Srivastava I.K., Stamatatos L., Legg L., Kan E., Fong A., Coates S.R., Leung L., Wininger M., Donnelly J.J., Ulmer J.B., Barnett S.W. Purification and characterization of oligomeric envelope glycoprotein from primary R5 subtype B human immunodeficiency virus. J. Virol. 2002, 76:2835-2847.
51. Tang B.C., Dawson M., Lai S.K., Wang Y.Y., Suk J.S., Yang M., Zeitlin P., Boyle M.P., Fu J., Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. USA. 2009, 106:19268-19273.
52. Tien D., Schnarre R.L., Kang G., Cohl G., McCormick T.J., Moench T.R., Doncel G., Watson K., Buckheit R.W., Lewis M.G., Schwartz J., Douville K., Romano J.W. In vitro and in vivo characterization of a potential universalplacebo designed for use in vaginal microbicideclinical trials. AIDS Res. Hum. Retrovir. 2005, 21:845-853.
53. Tuyama A.C., Cheshenko N., Carlucci M.J., Li J.H., Goldberg C.L., Waller D.P., Anderson R.A., Profy A.T., Klotman M.E., Keller M.J., Herold B.C. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J. Infect. Dis. 2006, 194:795-803.
54. Veazey R.S., Ling B., Green L.C., Ribka E.P., Lifson J.D., Piatak M., Lederman M.M., Mosier D., Offord R., Hartley O. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 2009, 199:1525-1527.
55. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that " slip" through the human mucus barrier. Angew. Chem. Int. Ed. Engl. 2008, 47:9726-9729.
56. Whaley K.J. Comments from the field: Broad-spectrum microbicides and reproductive health. The Microbicide Quarterly 2004, 2:11-13.
57. Whaley K.J., Barratt R.A., Zeitlin L., Hoen T.E., Cone R.A. Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J. Infect. Dis. 1993, 168:1009-1011.
58. Yu R.R., Cheng A.T., Lagenaur L.A., Huang W., Weiss D.E., Treece J., Sanders-Beer B.E., Hamer D.H., Lee P.P., Xu Q., Liu Y. A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J. Med. Primatol. 2009, 38:125-136.
59. Zeitlin L., Pauly M., Whaley K.J. Second-generation HIV microbicides: continued development of griffethsin. Proc. Natl. Acad. Sci. USA 2009, 106:6029-6030.
60. Zeitlin L., Whaley K.J., Hegarty T.A., Moench T.R., Cone R.A. Tests of vaginal microbicides in the mouse genital herpes model. Contraception 1997, 56:329-335.